Breast Cancer Core Needle Biopsy Market To Reach $1.15 Billion By 2030

Breast Cancer Core Needle Biopsy Market Growth & Trends

The global breast cancer core needle biopsy market size is estimated to reach USD 1.15 billion by 2030, registering to grow at a CAGR of 4.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

 Request a free sample copy or view report summary: Breast Cancer Core Needle Biopsy Market Report

Breast Cancer Core Needle Biopsy Market Report Highlights

• The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages.

• The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024.

• The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry.

• North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024.

Breast Cancer Core Needle Biopsy Market Segmentation

Grand View Research has segmented the global breast cancer core needle biopsy market based on technology, end-use, and region:

Breast Cancer Core Needle Biopsy Technology Outlook (Revenue, USD Million, 2018 - 2030)

• MRI-based Breast Biopsy

• Ultrasound-based Breast Biopsy

• Mammography-based (Stereotactic) Breast Biopsy

• CT-based Breast Biopsy

• Other Image Based Breast Biopsy

Breast Cancer Core Needle Biopsy End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Diagnostic Laboratories

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

Breast Cancer Core Needle Biopsy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Singapore

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Breast Cancer Core Needle Biopsy Market

• Intact Medical Corporation

• Ethicon Surgical Technologies

• Gallini SRL

• Leica Biosystems Nussloch GmbH

• Hologic, Inc.

• Argon Medical Devices

• Encapsule Medical Devices LLC

• Cook Medical Incorporated

• Becton, Dickinson and Company

• C.R. Bard, Inc.